General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor-β1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (Loma Linda, CA; Winston-Salem, NC, USA)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (Omaha, NE; Ocala, FL, USA)


Effect of GPIIb/IIIa Inhibition with Eptifibatide or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (Heidelberg; Tuebingen; Kirchheim; Solingen, Germany)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilament-directed Agents in Tumor Model Systems In Vivo. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (Syracuse, NY, USA)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (Columbus, OH; San Juan Capistrano, CA, USA)


Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (Jackson, MS, USA)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKESFELDT, J. ROSENBERG, I. GÖGENUR (Køge; Copenhagen; Herlev, Denmark)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIKOKOSKI, D. SAJUTHI, S.J. SCHAPIRO, A. GJEDDE, J. HAU (Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIKATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHRUBO (Tokyo; Saitama; Aichi, Japan)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUIJIKAWA, A. TANAKA (Kobe; Osaka; Saita; Kanan, Japan)


Instructions to Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapantrioti-Kalamou Road
   P.O. Box 22, GR-19014 Kapantriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (Beijing, China; Cardiff, UK)


Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (Boca raton, FL, USA)


Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (Bundooor; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia)


Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (Düsseldorf, Germany)


Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (Bucharest, Romania; Charlotte, MA, USA)
Predictors of Intrahepatic Multiple Recurrences After Curative Hepatectomy for Hepatocellular Carcinoma. K. TAKEISHI, T. MAEDA, E. TSUJITA, Y.-I. YAMASHITA, N. HARADA, S. ITOH, N. HARIMOTO, T. IKEGAMI, T. YOSHIZUMI, K. SHIRABE, Y. MAEHARA (Fukuoka; Hiroshima, Japan) ............................................................ 3061

No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. A. MIYAZAKI, H. MIYAKE, K.-I. HARADA, M. FUJISAWA (Kobe, Japan) ................................................................................................................................. 3067

The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. A. BOURDOUMIS, M. CHRISOFOS, T. STASINOU, P. CHRISTOPOULOS, P. MOURMOURIS, A. KOSTAKOPOULOS, C. DELIVELIOTIS (Torquay; Exeter; Manchester, UK; Athens, Greece) ............................................................................................................................. 3075


Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary. O. JAMY, G. YAGHMOUR, F. HARE, M.G. MARTIN (Memphis, TN, USA) .................................................................................................................. 3091

Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer. R. PETRIOLI, E. FRANCINI, A.I. FIASCHI, L. LAERA, S.T. MIANO, G. DE RUBERTIS, G. ROVIELLO (Siena; Rome, Italy) .................................................................................................................. 3097


Errata .................................................................................................................................................. 3109

Book Reviews ..................................................................................................................................... 3111

Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus. S. TAMURA, A. TAKENO, H. TANIGUCHI, Y. KATSURA, Y. OHMURA, Y. KAGAWA, H. SAKISAKA, Y. TAKEDA, T. KATO (Hyogo, Japan) .......................................................... 2975


Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer. E.M. AZZATO, C. DESHPANDE, V. AIKAWA, C. AGGARWAL, E. ALLEY, B. JACOBS, J. MORRISSETTE, R. DABER (Philadelphia, PA, USA) .......................................................................................... 3007

Radiation Therapy for Choroid Plexus Carcinoma Patients with Li-Fraumeni Syndrome: Advantageous or Detrimental? M. BAHAR, U. KORDES, T. TEKAUTZ, J. WOLFF (Cleveland, OH, USA; Hamburg, Germany) .................................................................................. 3013

Thymidine Kinase Levels Correlate with Prognosis in Aggressive Lymphoma and Can Discriminate Patients with a Clinical Suspicion of Indolent to Aggressive Transformation. M.E. GATT, N. GOLDSCHMIDT, I. KALICHMAN, M. FRIEDMAN, A.C. ARRONSON, V. BARAK (Jerusalem, Israel) .................................................................................. 3019

Does the Diagnosis Center Influence the Prognosis of Ovarian Cancer Patients Submitted to Neoadjuvant Chemotherapy? G. VIZZIELLI, F. FANFANI, V. CHIANTERA, L. TORTORELLA, A. LUCIDI, M. PETRILLO, B. COSTANTINI, G. SCAMBIA, A. FAGOTTI (Rome; Campobasso; Ternt, Italy) .......... 3027


Single-phase Whole-body 64-MDCT Split-bolus Protocol for Pediatric Oncology: Diagnostic Efficacy and Dose Radiation. M. SCIALPI, R. SCHIAVONE, A. D’ANDREA, I. PALUMBO, M. MAGLI, S. GRAVANTE, G. FALCONE, C. DE FILIPPI, B. PALUMBO (Perugia; Florence; Parma; Caserta; Rome, Italy) ............. 3041

Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Monoclinical Phase II Study. F. TRAMACERE, S. ARCANGELI, A. PIGNATELLI, R. CASTAGNA, M. PORTALURI (Brindisi; Rome; Pisa, Italy) ......................................................... 3049


Contents continued on the preceding page
Recurrence 11 Years After Complete Response to Gemcitabine, 5-Fluorouracil, and Cisplatin Chemotherapy Followed by Radiotherapy in a Patient with Advanced Pancreatic Cancer: a Case Report. T. UCHIHARA, Y.-I. YAMASHITA, W. HUALIN, K. TAKEISHI, S. ITOH, N. HARIMOTO, T. YOSHIZUMI, S. AISHIMA, K. SHIRABE, H. BABA, Y. MAEHARA (Fukuoka; Kumamoto; Saga, Japan) ........................................ 2867

A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients. S. VASILYEV, E. SMIRNOVA, D. POPOV, A. SEMENOV, C. EKLUND, P. HENDOLIN, L. PALOHEIMO, K. SYRJÄNEN (St. Petersburg, Russia; Helsinki, Finland; Barretos, SP, Brazil) .............................................................. 2873

Development and Validation of a Nomogram to Estimate the Risk of Prostate Cancer in Brazil. T.B. SILVA, C.Z. OLIVEIRA, E.F. FARIA, E.C. MAUAD, K.J. SYRJÄNEN, A.L. CARVALHO (Barretos, SP, Brazil; Helsinki, Finland) ............................................................................................ 2881

Impact of Surgical Case Volume on the Accuracy of Preoperative Staging and Compliance with the Guidelines for the Management of Endometrial Cancer. M. KOSKAS, L. OULDAMER, N. BOUREL, T. GAUTHIER, J.-L. BRUN, C. HUCHON (Paris; Tours; Clermont Ferrand; Limoges; Bordeaux; Poissy, France) ......................... 2887

Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer. A. RABINOVICH, L. BERNARD, T.M. NIAZI, A.V. RAMANAKUMAR, W.H. GOTLIEB, S. LAU, B. BAHORIC (Montreal, Quebec, Canada) ........................................................................ 2893

Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendrogliom Tumors Treated with the PCV Regimen. E. TABORET, G. REYES-BOTERO, C. DEHAIS, M. DAROS, M. BARRIE, M. MATTA, G. PETRIRENA, D. AUTRAN, A. DURAN, C. BEQUET, J.-Y. DELATTRE, O. CHINOT (Marseille; Paris, France) ........................................................................... 2901

Construction of a Model for Predicting Creatinine Clearance in Japanese Patients Treated with Cisplatin Therapy. A. YAJIMA, Y. UESAWA, C. OGAWA, M. YATABE, N. KONDO, S. SAITO, Y. SUZUKI, K. ATSUDA, H. KAGAYA (Tokyo; Chiba; Kanagawa, Japan) ................................................................. 2909

Positive Interplay Between CD3\(^+\) T-lymphocytes and Concurrent COX-2/EGFR Expression in Canine Malignant Mammary Tumors. M.I. CARVALHO, I. PIRES, J. PRADA, A.F. FERREIRA, F.L. QUEIROGA (Vila Real; Porto, Portugal; Sousa, PB, Brazil) .................................................................................. 2915

Significance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma. T. OCHIAI, H. ISHII, Y. YAMAMOTO, R. MORIMURA, H. IKOMA, E. OSTSUI (Kyoto, Japan) ............................................................................. 2921

Impact of Nagasaki Atomic Bomb Exposure on Myelodysplastic Syndrome Patients Who Are Treated with Azacitidine. T. JO, K. HORIO, K. SHIGEMATSU (Nagasaki, Japan) ..................................................... 2929


Interleukin-32 Expression and Treg Infiltration in Esophageal Squamous Cell Carcinoma. B. NABEKI, S. ISHIGAMI, Y. UCHIKADO, K. SASAKI, Y. KITA, H. OKUMURA, T. ARIGAMI, Y. KIJIIMA, H. KURAHARA, K. MAEMURA, S. NATSUGOE (Kagoshima, Japan) ............................................. 2941

The Prognostic Role of Claudins -1 and -4 in Oral Squamous Cell Carcinoma. J.C. DE VICENTE, Á. FERNÁNDEZ-VALLE, B. VIVANCO-ALLENDE, T.R. SANTAMARTA, P. LEQUERICA-FERNÁNDEZ, G. HERNÁNDEZ-VALLEJO, E. ALLONCA-CAMPA (Oviedo; Madrid, Spain) ........................................... 2949

Profile of Serum Factors and Disseminated Tumor Cells Before and After Radiofrequency Ablation Compared to Resection of Colorectal Liver Metastases-A Pilot Study. S. HINZ, J. TEPEL, C. RÖDER, H. KALTHOFF, T. BECKER (Kiel; Osnabrück, Germany) ............................................................................................. 2961

Contents continued on the preceding page
Expression of Formyl-peptide Receptors in Human Lung Carcinoma. F. CATTANEO, G. GUERRA, M. PARISI, A. LUCARIELLO, A. DE LUCA, N. DE ROSA, G. MAZZARELLA, A. BIANCO, R. AMMENDOLA (Naples; Campobasso, Italy) .............................................................. 2769


Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models. L. ARZUMAN, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Concord, Australia) ............................................................... 2783


Evaluation of Stem Cell Marker Expression in Canine B-Cell Lymphoma Cell Lines, B-Cell Lymphoma-generated Spheres and Primary Samples. W. LIU, F. SELÇUK, B.C. RÜTGEN, M. MOULAY, S. WILLENBROCK, S.E. HAMMER, K.A. STERENCZAK, C. JUNGHANSS, M. HEWICKER-TRAUTWEIN, I. NOLTE, H.M. ESCOBAR (Hannover; Rostock, Germany; Vienna, Austria) .......................................................... 2805

Amifostine Increases FAS and Caspase-3 Expression in Colonic Tissue of Irradiated Mice. C.T.F. OSHIMA, D.A. RIBEIRO, T.S. GOMES, P.C. ADIOS, M.I. EGAMI, H.R.C. SEGRETO (São Paulo, SP, Brazil) .......... 2817

Circulating Tumour Cells in Patients with Malignant Lung Tumors Undergoing Radio-frequency Ablation. D. CHUDASAMA, A. RICE, V. ANIKIN, G. SÖPPA, P. DALAL (Harefield, Middlesex, UK) .......................................................... 2823

Lupalbigenin from Derris scandens Sensitizes Detachment-induced Cell Death in Human Lung Cancer Cells. A. AUSAWASAMRIT, N. ITTHIWARAPORNKUL, C. CHAO Thom, S. SUKRONG, P. CHANVORACHOTE (Bangkok, Thailand) .......................................................... 2827


Clinical Studies


Serum Angiopoietin-like Protein 2 Improves Preoperative Detection of Lymph Node Metastasis in Colorectal Cancer. Y. TOIYAMA, Y. INOUE, T. SHIMURA, H. FUJIKAWA, S. SAIGUSA, J. HIRO, M. KOBAYASHI, M. OHI, T. ARAKI, K. TANAKA, Y. MOHR, M. KUSUNOKI (Mie, Japan) .......................................................... 2849

Radiation-induced Chondrosarcoma of the Bladder. Case Report and Review of Literature. N. SULE, B. XU, D. EL ZEIN, K. SZIGETI, S. GEORGE, J.M. KANE, R. CHENEY (Buffalo, NY, USA) .......................................................... 2857

Absolute Lymphocyte Count with Extreme Hyperleukocytosis Does Not Have a Prognostic Impact in Chronic Lymphocytic Leukemia. L. SHVIDEL, O. BAI REY, T. TAM MOR, A. BRAESTER, R. RUCHLEMER, R. FINEMAN, E. JOFFE, A. BERREBI, A. POLLIA CK (Rehovot; Petah-Tikva; Haifa; Naharia; Jerusalem, Israel) .......................................................... 2861
Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer. T.H. ECKE, C. ARNDT, C. STEPHAN, S. HALLMANN, O. LUX, T. OTTO, J. RUTTLOFF, H. GERULLIS (Bad Saarow; Neuss; Berlin; Oldenburg, Germany) 2651

Cytotoxicity of Endogenous Lipids N-acyl Dopamines and their Possible Metabolic Derivatives for Human Cancer Cell Lines of Different Histological Origin. M.G. AKIMOV, N.M. GRETSKAYA, G.N. ZINCHENKO, V.V. BEZUGLOV (Moscow, Russia) 2657

Pentraxin-3 Silencing Suppresses Gastric Cancer-related Inflammation by Inhibiting Chemotactic Migration of Macrophages. B. CHOI, E.-J. LEE, Y.S. PARK, S.-M. KIM, E.-Y. KIM, Y. SONG, S.-W. KANG, M.-H. RHU, E.-J. CHANG (Seoul, Republic of Korea) 2663

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response. T. OHASHI, T. YOSHIMASU, S. OURA, Y. KOKAWA, M. KAWAGO, Y. HIRAI, M. MIYASAKA, Y. AOISHI, M. KIYOI, H. NISHIGUCHI, M. HONDA, Y. OKAMURA (Wakayama, Japan) 2669

Enhanced Antiproliferative and Pro-apoptotic Activities of a Novel Curcumin-related Compound in Jurkat Leukemia T-Cells. K. GOLDHAHN, M. HINTERSTEININGER, G. STEINER, T. ERKER, B. KLOESCH (Vienna, Austria) 2675

Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. J. LOHR, A. MOCK, P. BECKHOVE, C. HEROLD-MENDE (Heidelberg, Germany) 2681

Demethoxycurcumin-induced DNA Damage Decreases DNA Repair-associated Protein Expression Levels in NCI-H460 Human Lung Cancer Cells. Y.-C. KO, J.-C. LIEN, H.-C. HSU, Y.-Y. LIN, F.-S. CHUEH, B.-C. JI, M.-D. YANG, W.-H. HSU, J.-G. CHUNG (Taichung; Changhua, Taiwan, ROC) 2691

Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress. G.B. PARK, D.Y. HUR, D. KIM (Busan, Republic of Korea) 2699

Analyses of EGF A61G Gene Variation and Serum EGF Level on Gastric Cancer Susceptibility and Clinicopathological Parameters. C. CACINA, S. ARIKAN, Y. DÜZKÖYLÜ, M.B. DOĞAN, E. OKAY, S. TURAN, I. YAYLIM, T. İSBİR (Istanbul; Kocaeli, Turkey) 2709

Identification, Molecular Characterization and Alternative Splicing of Three Novel Members of the Canine Kallikrein (Klk)-related Peptidase Family. K. ANGELOPOULOU, G.S. KARAGIANNIS (Thessaloniki, Greece; Toronto, Canada) 2715


Gemcitabine Induces Radiosensitization Through Inhibition of RAD51-dependent Repair for DNA Double-strand Breaks. S. KOBASHIGAWA, K. MORIKAWA, H. MORI, G. KASHINO (Oita; Fukuoka, Japan) 2731

Azaspirene Analogs Inhibit the Growth of Human Uterine Carcinosarcoma In Vitro and In Vivo. M. EMOTO, K. YANO, B. CHOIJAMTS, S. SAKAI, S. HIRASAWA, S. WAKAMORI, M. AIZAWA, K. NABESHIMA, K. TACHIBANA, N. KANOMATA (Fukuoka; Tokyo; Kawasaki, Japan) 2739

Expression of miRNAs as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli. M. WOZNIAK, M. SZTILLER-SIKORSKA, M. CZYZ (Lodz, Poland) 2747

Early Reporting of Apoptosis by Real-time Imaging of Cancer Cells Labeled with Green Fluorescent Protein in the Nucleus and Red Fluorescent Protein in the Cytoplasm. M. YANG, P. JIANG, R.M. HOFFMAN (San Diego, CA, USA; Beijing, PR China) ................................................................. 2539

Imaging the Interaction of Pancreatic Cancer and Stellate Cells in the Tumor Microenvironment during Metastasis. A. SUETSUGU, C.S. SNYDER, H. MORIWAKI, S. SAJI, M. BOUVET, R.M. HOFFMAN (San Diego, CA, USA; Gifu, Japan) ......................................................... 2545

The Use of Living Cancer Cells Expressing Green Fluorescent Protein in the Nucleus and Red Fluorescence Protein in the Cytoplasm for Real-time Confocal Imaging of Chromosome and Cytoplasmic Dynamics During Mitosis. A. SUETSUGU, P. JIANG, M. YANG, N. YAMAMOTO, H. MORIWAKI, S. SAJI, R.M. HOFFMAN (San Diego, CA, USA; Gifu; Kanazawa, Japan; Beijing, PR China) ................................................................. 2553


Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy. L.V. KLOTZ, D.-A. CLEVERT, S. SCHECKINGER, S. STRIETH, M.E. EICHHORN (Munich; Mainz; Heidelberg, Germany) ................. 2571

High-dose Ionizing Radiation Regulates Gene Expression Changes in the MCF7 Breast Cancer Cell Line. V. BRAVATÁ, L. MINAFRA, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, C. CASARINO, G. AUGELLO, F. COSTANTINI, G. BARBIERI, C. MESSA, M.C. GILARDI (Cefalù; Palermo; Milan; Monza, Italy) ................................................................. 2577

Differential Gene Expression of the Proto-oncogene VAV3 and the Transcript Variant VAV3.1 in Oral Squamous Cell Carcinoma. T. TRENKLE, S.G. HAKIM, H.-C. JACOBSEN, P. SIEG (Lübeck, Germany) .............. 2593

A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer. Y. AMEMIYA, S. BACOPULOS, M. AL-SHAWARBY, D. AL-TAMIMI, W. NASER, A. AHMED, M. KHALIFA, E. SLODKOWSKA, A. SETH (Toronto, ON, Canada; Dammam, Kingdom of Saudi Arabia) ................................................................. 2601


Down-regulation of Immune-related Genes by PSCA in Gallbladder Cancer Cells Implanted into Mice. N. SAEDI, H. ONO, H. SAKAMOTO, T. YOSHIDA (Tokyo, Japan) ................................................................. 2619

Reduced UDP-glucose Levels Are Associated with P-glycoprotein Over-expression in L1210 Cells and Limit Glucosylceramide Synthase Activity. K. TURÁKOVÁ, L. PAVLÍKOVÁ, L. MESSINGEROVÁ, B. LAKATOŠ, A. BREIER, Z. SULOVÁ (Bratislava, Slovak Republic) ................................................................. 2627

Epithelial-mesenchymal Transition (EMT) Markers in Human Pituitary Adenomas Indicate a Clinical Course. W. JIA, J. ZHU, T.A. MARTIN, A. JIANG, A.J. SANDERS, W.G. JIANG (Beijing; Shandong; YanTai, PR China; Cardiff, UK) ................................................................. 2635

Kaempferol Is an Anti-Inflammatory Compound with Activity towards NF-κB Pathway Proteins. O. KADIOGLU, J. NASS, M.E.M. SAEED, B. SCHULER, T. EFFERTH (Mainz; Freiburg, Germany) ....... 2645

Contents continued on the preceding page